You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Comprehensive Review of Emergence and Virology of Tickborne Bourbon Virus in the United States

  • Authors: Molly K. Roe, BS; Elise R. Huffman, BS; Yara S. Batista, BS; George G. Papadeas, BS; Sydney R. Kastelitz, BS; Anna M. Restivo, BS; Christopher C. Stobart, PhD
  • CME / ABIM MOC Released: 12/21/2022
  • Valid for credit through: 12/21/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for infectious disease specialists and other healthcare professionals who see patients with rare viral illnesses.

The goal of this activity is for learners to be better able to describe the virology and clinical characteristics of Bourbon Virus infection.

Upon completion of this activity, participants will:

  • Assess the virology of the Bourbon Virus
  • Distinguish the geographic distribution of the Bourbon Virus infection in the US
  • Evaluate the transmission of the Bourbon Virus
  • Assess the clinical picture of the Bourbon Virus infection


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Molly K. Roe, BS

    Department of Biological Sciences
    Butler University
    Indianapolis, Indiana

  • Elise R. Huffman, BS

    Department of Biological Sciences
    Butler University
    Indianapolis, Indiana

  • Yara S. Batista, BS

    Department of Biological Sciences
    Butler University
    Indianapolis, Indiana

  • George G. Papadeas, BS

    Department of Biological Sciences
    Butler University
    Indianapolis, Indiana

  • Sydney R. Kastelitz, BS

    Department of Biological Sciences
    Butler University
    Indianapolis, Indiana

  • Anna M. Restivo, BS

    Department of Biological Sciences
    Butler University
    Indianapolis, Indiana

  • Christopher C. Stobart, PhD

    Department of Biological Sciences
    Butler University
    Indianapolis, Indiana

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine School of Medicine

    Disclosures

    Charles P. Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Editor

  • Susan Zunino, PhD

    Copyeditor
    Emerging Infectious Diseases

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit(s)™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Comprehensive Review of Emergence and Virology of Tickborne Bourbon Virus in the United States

Authors: Molly K. Roe, BS; Elise R. Huffman, BS; Yara S. Batista, BS; George G. Papadeas, BS; Sydney R. Kastelitz, BS; Anna M. Restivo, BS; Christopher C. Stobart, PhDFaculty and Disclosures

CME / ABIM MOC Released: 12/21/2022

Valid for credit through: 12/21/2023, 11:59 PM EST

processing....

Abstract and Introduction

Abstract

The emergence of SARS-CoV-2 and the worldwide COVID-19 pandemic triggered considerable attention to the emergence and evolution of novel human pathogens. Bourbon virus (BRBV) was first discovered in 2014 in Bourbon County, Kansas, USA. Since its initial discovery, several cases of BRBV infection in humans have been identified in Kansas, Oklahoma, and Missouri. BRBV is classified within the Thogotovirus genus; these negative-strand RNA viruses appear to be transmitted by ticks, and much of their biology remains unknown. In this review, we describe the emergence, virology, geographic range and ecology, and human disease caused by BRBV and discuss potential treatments for active BRBV infections. This virus and other emerging viral pathogens remain key public health concerns and require continued surveillance and study to mitigate human exposure and disease.

Introduction

The first case of Bourbon virus (BRBV) was identified in June 2014 in Bourbon County, Kansas, USA, after severe febrile illness developed in a previously healthy middle-aged (>50 years of age) man[1]. Several days after he removed an engorged tick from his shoulder, nonspecific symptoms of disease appeared. After 3 days of worsening fever, myalgia, arthralgia, and diarrhea, the patient visited his primary care physician and was prescribed doxycycline. The next day, the patient was admitted to the hospital because of dehydration, syncope, and a possible tickborne illness. Doxycycline treatment was continued; however, the patient did not respond, and symptoms continued to progress toward multiorgan failure. Laboratory results revealed progressive leukopenia and thrombocytopenia (which are now considered identifiers of potential BRBV infection). Patient blood samples tested negative for all known regional tickborne diseases. Therefore, a whole blood sample was sent to the US Centers for Disease Control and Prevention (CDC) to test for Heartland virus (HRTV), a similar emerging tickborne virus in the region. The index patient died 11 days after symptom onset.

Initial efforts at CDC to identify the causative agent of disease in this first case revealed heterologous (non-HRTV) viral plaques in plaque reduction neutralization tests performed by using serum from the deceased patient and including a control HRTV strain. Subsequent electron microscopy revealed pleiomorphic viral particles consistent with the family Orthomyxoviridae[1]. Phylogenetic analyses revealed a close relationship between the patient’s novel virus and Thogoto and Dhori viruses, placing it within the genus Thogotovirus. Subsequent genetic analyses supported this initial genus classification[2,3]. Recently, another novel thogotovirus (Oz virus) was discovered in ticks in Japan; this virus was capable of replicating in mammalian cell lines and is the closest known relative of BRBV[3]. BRBV was the first human pathogen in the genus Thogotovirus identified in the Western Hemisphere; Aransas Bay virus, another pathogenic member of this genus, was reported in ticks found in seabird nests in the United States[2]. Since its initial identification, ≥5 human cases of BRBV-associated disease have been reported in the Midwest region of the United States[1,4–8]. Because little is known about BRBV biology and no specific treatments or vaccines are available, further studies of BRBV are needed.